252555-01-4
252555-01-4 結(jié)構(gòu)式
基本信息
BYQDPIXWTVEVEA-JMAPEOGHSA-N
(2S)-3-(4-hydroxyphenyl)-4-methyl-2-[4-[2-(1-piperidyl)ethoxy]phenyl]-2H-chromen-7-ol
(2S)-3-(4-hydroxyphenyl)-4-methyl-2-[4-(2-piperidin-1-ylethoxy)phenyl]-2H-chromen-7-ol,hydrochloride
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
| 2024/11/08 | HY-16023 | (2S)-3-(4-hydroxyphenyl)-4-methyl-2-[4-[2-(1-piperidyl)ethoxy]phenyl]-2H-chromen-7-ol Acolbifene hydrochloride | 252555-01-4 | 5mg | 1800元 |
| 2024/11/08 | HY-16023 | (2S)-3-(4-hydroxyphenyl)-4-methyl-2-[4-[2-(1-piperidyl)ethoxy]phenyl]-2H-chromen-7-ol Acolbifene hydrochloride | 252555-01-4 | 10mM * 1mLin DMSO | 1956元 |
| 2024/11/08 | HY-16023 | (2S)-3-(4-hydroxyphenyl)-4-methyl-2-[4-[2-(1-piperidyl)ethoxy]phenyl]-2H-chromen-7-ol Acolbifene hydrochloride | 252555-01-4 | 10mg | 2900元 |
常見問(wèn)題列表
|
Estrogen receptor 0.110 nM (IC 50 ) |
Acolbifene (ACOL) does not affect pathways of cholesterol synthesis, supporting the involvement of the clearance-related receptors in its hypocholesterolemic action.
Acolbifene (EM-652) shows no agonistic activity on ERα and ERβ transcriptional function and blocks the estradiol (E2)-mediated activation of both ERα and ERβ.
Acolbifene (EM-652) shows the most potent inhibition of estradiol-stimulated cell proliferation in human breast cancer cells (ZR-75-1, MCF-7, T-47D) and is devoid of any intrinsic estrogenic activity.
Acolbifene (ACOL) reduces food intake and strongly decreases cholesterolemia in rats fed a cholesterol-free diet.
Acolbifene (ACOL) reduces food intake (16%) and weight gain (45%, mainly fat) similarly in both dietary cohorts.
| Animal Model: | Female Sprague-Dawley rats (n = 42) initially weighing 175-200 g. |
| Dosage: | 2.5 mg/kg. |
| Administration: | Oral gavage, once daily for 21 d. |
| Result: | Prevents tumor growth in rats. |